JAMP-TERBINAFINE TABLET
Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
Ciri produk
(SPC)
23-09-2010
Beberapa dokumen untuk produk ini saat ini tidak tersedia, anda dapat mengirim permintaan ke layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami dapat memperolehnya.
Hantar permintaan.
Hantar permintaan.
Bahan aktif:
TERBINAFINE (TERBINAFINE HYDROCHLORIDE)
Boleh didapati daripada:
JAMP PHARMA CORPORATION
Kod ATC:
D01BA02
INN (Nama Antarabangsa):
TERBINAFINE
Dos:
250MG
Borang farmaseutikal:
TABLET
Komposisi:
TERBINAFINE (TERBINAFINE HYDROCHLORIDE) 250MG
Laluan pentadbiran:
ORAL
Unit dalam pakej:
30/100
Jenis preskripsi:
Prescription
Kawasan terapeutik:
ALLYLAMINES
Ringkasan produk:
Active ingredient group (AIG) number: 0132855002; AHFS:
Status kebenaran:
CANCELLED POST MARKET
Tarikh kebenaran:
2022-09-07
Ciri produk
Page 1 of 33
PRODUCT MONOGRAPH
PR
JAMP-TERBINAFINE
Terbinafine Tablets
(250 mg Terbinafine as Terbinafine Hydrochloride)
ANTIFUNGAL AGENT
JAMP PHARMA CORPORATION
DATE OF PREPARATION:
1380 – 203 Newton Street
September 16, 2010
Boucherville, Quebec
J4B 5H2
Control#: 141429
Page 2 of 33
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
...............................................................................3
INDICATIONS AND CLINICAL
USE.....................................................................................3
CONTRAINDICATIONS
..........................................................................................................4
WARNINGS AND
PRECAUTIONS.........................................................................................4
ADVERSE
REACTIONS...........................................................................................................6
DRUG INTERACTIONS
...........................................................................................................8
DOSAGE AND
ADMINISTRATION.......................................................................................9
OVERDOSAGE
.......................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
...................................................................10
STORAGE AND
STABILITY.................................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL
INFORMATION.................................................................................13
CLINICAL
TRIALS.................................................................................................................14
DETAI
Baca dokumen lengkap
